Rituximab treatment of adults with primary focal segmental glomerulosclerosis

To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liuwei, Yu, Lu, Wang, Yulin, Guo, Yanhong, Zhai, Zihan, Tang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130152/
https://www.ncbi.nlm.nih.gov/pubmed/37185370
http://dx.doi.org/10.1038/s41598-023-33678-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130152/
https://www.ncbi.nlm.nih.gov/pubmed/37185370
http://dx.doi.org/10.1038/s41598-023-33678-y

Ejemplares similares